Source:http://linkedlifedata.com/resource/pubmed/id/12838283
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions |
umls-concept:C0006142,
umls-concept:C0021083,
umls-concept:C0024299,
umls-concept:C0030685,
umls-concept:C0040736,
umls-concept:C0079189,
umls-concept:C0205263,
umls-concept:C0391871,
umls-concept:C0439662,
umls-concept:C0680255,
umls-concept:C1283071,
umls-concept:C1519043,
umls-concept:C1879547,
umls-concept:C1963578
|
pubmed:issue |
2
|
pubmed:dateCreated |
2003-7-2
|
pubmed:abstractText |
We determined the safety, immune activating effects, and potential efficacy of i.v. infusion of ex vivo interleukin-2 (IL-2) activated natural killer (NK) cells (part I) or IL-2 boluses (part II) during daily s.c. IL-2 administration following hematopoietic recovery from autologous transplantation. In all, 57 patients with relapsed lymphoma (n=29) or metastatic breast cancer (n=28) were enrolled. In part I of the study, 34 patients were enrolled at three dose levels of ex vivo IL-2-activated NK cells. Lymphaphereses were performed on days 28 and 42 of s.c. IL-2 administration. Following overnight ex vivo IL-2 activation of the pheresis product, the cells were reinfused the following day. In part II, 23 patients were enrolled at three dose levels of supplemental i.v. IL-2 bolus infusions, given on days 28 and 35 during s.c. IL-2 administration. Toxicities were generally mild, and no patient required hospitalization. Lytic function was markedly enhanced for fresh peripheral blood mononuclear cells (PBMNCs) obtained 1 day postinfusion of either IL-2-activated cells or IL-2 boluses. IL-2 boluses transiently increased the levels of IL-6, IFN-gamma, TNF-alpha and IL1-beta, with increases in IL-6 and IFN-gamma being dose dependent. A total of 37 patients (19 patients with lymphoma, 18 with breast cancer) treated with an optimum dose of post-transplant immunotherapy (defined as having received 1.75 x 10(6) IU/m(2)/day of s.c. IL-2 plus at least one of the planned ex vivo IL-2-activated cell infusions/IL-2 boluses) could be matched with controls from the Autologous Blood and Marrow Transplant Registry database. The matched-pairs analysis demonstrated no improvement in disease outcomes of survival and relapse. We conclude that IL-2-activated cells/IL-2 boluses can be safely administered, generate PBMNCs with enhanced cytotoxicity against NK-resistant targets, and increase cytokine levels. With this dose and schedule of administration of IL-2, no improvement in patient disease outcomes was noted. Alternative strategies will be needed to exploit the immunotherapeutic potential of IL-2-activated NK cells.
|
pubmed:grant | |
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Jul
|
pubmed:issn |
0268-3369
|
pubmed:author |
pubmed-author:BlazarB RBR,
pubmed-author:BurgerS RSR,
pubmed-author:BurnsL JLJ,
pubmed-author:DeForT ETE,
pubmed-author:Keever-TaylorC ACA,
pubmed-author:MillerJ SJS,
pubmed-author:Panoskaltsis-MortariAA,
pubmed-author:RepkaT LTL,
pubmed-author:VesoleD HDH,
pubmed-author:WeisdorfD JDJ,
pubmed-author:ZhangM-JMJ
|
pubmed:issnType |
Print
|
pubmed:volume |
32
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
177-86
|
pubmed:dateRevised |
2007-11-14
|
pubmed:meshHeading |
pubmed-meshheading:12838283-Adult,
pubmed-meshheading:12838283-Breast Neoplasms,
pubmed-meshheading:12838283-Cytokines,
pubmed-meshheading:12838283-Female,
pubmed-meshheading:12838283-Hematopoietic Stem Cell Transplantation,
pubmed-meshheading:12838283-Humans,
pubmed-meshheading:12838283-Immunity, Cellular,
pubmed-meshheading:12838283-Immunotherapy,
pubmed-meshheading:12838283-Interleukin-2,
pubmed-meshheading:12838283-Killer Cells, Natural,
pubmed-meshheading:12838283-Lymphocyte Transfusion,
pubmed-meshheading:12838283-Lymphoma,
pubmed-meshheading:12838283-Male,
pubmed-meshheading:12838283-Matched-Pair Analysis,
pubmed-meshheading:12838283-Middle Aged,
pubmed-meshheading:12838283-Transplantation, Autologous
|
pubmed:year |
2003
|
pubmed:articleTitle |
IL-2-based immunotherapy after autologous transplantation for lymphoma and breast cancer induces immune activation and cytokine release: a phase I/II trial.
|
pubmed:affiliation |
Blood and Marrow Transplant Program and Cancer Center, University of Minnesota, Mayo Mail Code 286, Minneapolis, MN 55455, USA.
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, U.S. Gov't, P.H.S.,
Research Support, U.S. Gov't, Non-P.H.S.,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase II,
Clinical Trial, Phase I
|